Abstract

BackgroundYoung men who have sex with men (YMSM) are disproportionately at risk for HIV and sexually transmitted infections. Adapting and testing the effectiveness of the Young Men’s Health Project (YMHP), an efficacious intervention designed to reduce substance use and condomless anal sex (CAS) among YMSM, at clinics in Miami, Detroit, and Philadelphia has the potential to reduce HIV and STI disparities among urban YMSM.ObjectiveThis study (Adolescent Medicine Trials Network for HIV/AIDS Interventions [ATN] 145 YMHP) aims to adapt YMHP for clinic and remote delivery by existing clinic staff and compare their effectiveness in real-world adolescent HIV clinics. This protocol is part of the ATN Scale It Up program described in a recently published article by Naar et al.MethodsThis is a comparative effectiveness hybrid type-2 trial of the YMHP intervention with 2 delivery formats—clinic-based versus remote delivery—offered following HIV counseling and testing. Phase 1 includes conducting focus groups with youth to obtain implementation feedback about the delivery of the YMHP intervention and intervention components to ensure culturally competent, feasible, and scalable implementation. Phase 2 includes recruitment and enrollment of 270 YMSM, aged 15 to 24 years, 90 at each of the 3 sites. Enrollment will be limited to HIV-negative YMSM who report recent substance use and either CAS or a positive STI test result. Participants will be randomized to receive the YMHP intervention either in person or by remote delivery. Both conditions involve completion of the 4 YMHP sessions and the delivery of pre-exposure prophylaxis information and navigation services. A minimum of 2 community health workers (CHWs) will be trained to deliver the intervention sessions at each site. Sessions will be audio-recorded for Motivational Interviewing Treatment Integrity (MITI) fidelity coding, and CHWs and supervisors will be given implementation support throughout the study period.ResultsPhase 1 focus groups were completed in July 2017 (n=25). Feedback from these focus groups at the 3 sites informed adaptations to the YMHP intervention manual, implementation of the intervention, and recruitment plans for phase 2. Baseline enrollment for phase 2 began in November 2018, and assessments will be at immediate posttest (IP)-, 3-, 6-, 9-, and 12-months after the intervention. Upon collection of both baseline and follow-up data, we will compare the effectiveness and cost-effectiveness of clinic-based versus remote delivery of YMHP in the context of health care access.ConclusionsWe are conducting YMHP in 3 cities with high rates of YMSM at risk for HIV and STIs. When adapted for real-world clinics, this study will help substance-using YMSM at risk for HIV and STIs and allow us to examine differences in effectiveness and cost by the method of delivery.Trial RegistrationClinicalTrials.gov NCT03488914; https://clinicaltrials.gov/ct2/show/NCT03488914 (Archived by WebCite at http://www.webcitation.org/770WaWWfi)International Registered Report Identifier (IRRID)DERR1-10.2196/11184

Highlights

  • The HIV Surveillance Report is published annually by the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S Department of Health and Human Services, Atlanta, Georgia

  • The term HIV infection, stage 3 (AIDS), and its condensed version—stage 3 (AIDS)— refer to persons with diagnosed HIV whose infection was classified as stage 3 (AIDS) during a given year or whose infection has ever been classified as stage 3 (AIDS)

  • Rates are not calculated by transmission category because of the lack of denominator data. b Includes Asian/Pacific Islander legacy cases. c Hispanics/Latinos can be of any race. d Heterosexual contact with a person known to have, or to be at high risk for, HIV infection. e Includes hemophilia, blood transfusion, and risk factor not reported or not identified. f Because column totals for estimated numbers were calculated independently of the values for the subpopulations, the values in each column may not sum to the column total

Read more

Summary

Suggested citation

Confidential information, referrals, and educational material on HIV infection CDC-INFO 1-800-232-4636 (in English, en Español) 1-888-232-6348 (TTY) http://www.cdc.gov/cdc-info/requestform.html

DEFINITIONS AND DATA SPECIFICATIONS
HIGHLIGHTS OF ANALYSES
Diagnoses of HIV infection
Deaths of persons with diagnosed HIV infection
Survival after a diagnosis of HIV infection
Prevalence of diagnosed HIV infection
ADDITIONAL RESOURCES
SUGGESTED READINGS
SURVEILLANCE OF HIV INFECTION
STAGES OF HIV INFECTION
TABULATION AND PRESENTATION OF DATA
Survival Analyses
Race and Ethnicity
Geographic Designations
Metropolitan Statistical Areas
Transmission Categories
Reporting Delays
Region of residence Northeast Midwest South West
Injection drug use Heterosexual contacte Otherf
Injection drug use
Injection drug use Heterosexual contactd Othere
Perinatal Otherf
Heterosexual contacte
Perinatal Otherg
South America
No of persons
Injection drug use Heterosexual contacte
Republic of Palau
Adults and adolescents Children
Alaska Native
MSA of residence
Nonmetropolitan areas
Adults or adolescents
Findings
Web Addresses for Reports of State and Local HIV Surveillance
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call